<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='144'><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="623">Head and neck tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A phase I/II, open-label, randomized, dose-ranging study to assess optimum dose, safety,and efficacy of Multikine in head and neck cancer patients</ProtocolTitle><Trial id="41757"/><TrialEndDateActual/><TrialEndDateCalc>2000-06-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1996-07-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Efficacy</Endpoint><Indication id="623">Head and neck tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>A phase I/II, multi-center, clinico-pathological study of Multikine in patients with advanced primary oral squamous cell carcinoma</ProtocolTitle><Trial id="41872"/><TrialEndDateActual/><TrialEndDateCalc>2002-12-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1998-12-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="55115">AFTVac</Drug><Endpoint>Efficacy</Endpoint><Indication id="3657">Metastatic breast cancer</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1</Patients><ProtocolTitle>A case study of bone-metastatic breast cancer with autologous formalin-fixed tumor vaccine</ProtocolTitle><Trial id="130015"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="755">Lung tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Trial id="28011"/><TrialEndDateActual/><TrialEndDateCalc>2004-05-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3673">Metastatic head and neck cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>928</Patients><ProtocolTitle>Efficacy and Safety Study of Leukocyte Interleukin, Injection (LI) to Treat Cancer of the Oral Cavity</ProtocolTitle><Trial id="73333"/><TrialEndDateActual/><TrialEndDateCalc>2014-12-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1261">Small-cell lung cancer</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>108</Patients><ProtocolTitle>A phase II, multicenter, randomized, open-label, parallel-group study to assess the safety and efficacy of EMD-273066 following low-dose cyclophosphamide compared to supportive care alone in patients with small cell lung cancer</ProtocolTitle><Trial id="89159"/><TrialEndDateActual>2010-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-09-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-03-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="79967">interleukin-2 follow-on-biologic, Zenotech</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1766">Renal cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A multicenter, phase III, safety and efficacy study of interleukin-2 follow-on-biologic, Zenotech in patients with renal cell carcinoma</ProtocolTitle><Trial id="271068"/><TrialEndDateActual/><TrialEndDateCalc>2008-09-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="1240">Mesothelioma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3667">Metastatic esophageal cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3866">Metastatic ovary cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="2446">Leiomyosarcoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Trial id="312527"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74941">SO-C101</Drug><Endpoint>Efficacy</Endpoint><Indication id="2054">Hematological neoplasm</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase I, clinical study of SO-C101 in patients with both solid tumors and hematological malignancies</ProtocolTitle><Trial id="352032"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="4250">Metastatic renal cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>600</Patients><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)</ProtocolTitle><Trial id="358884"/><TrialEndDateActual/><TrialEndDateCalc>2022-11-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2024-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2024-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2018-12-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="54">Carcinoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>27</Patients><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Trial id="28529"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-10-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="316">B-cell lymphoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Trial id="337393"/><TrialEndDateActual/><TrialEndDateCalc>2023-06-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-11-17 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-11-17 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="319">Non-Hodgkin lymphoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Trial id="337393"/><TrialEndDateActual/><TrialEndDateCalc>2023-06-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-11-17 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-11-17 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="3713">Advanced solid tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>230</Patients><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS-4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="372173"/><TrialEndDateActual/><TrialEndDateCalc>2022-06-01 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-02-28 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2019-02-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="623">Head and neck tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>A phase I, safety and efficacy study of Multikine in patients with head and neck cancer</ProtocolTitle><Trial id="41756"/><TrialEndDateActual/><TrialEndDateCalc>2001-08-14 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-09-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1766">Renal cell carcinoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Trial id="28011"/><TrialEndDateActual/><TrialEndDateCalc>2004-05-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="54">Carcinoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Trial id="28011"/><TrialEndDateActual/><TrialEndDateCalc>2004-05-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="63685">ALT-801 (donor lymphocyte infusion, cancer), Altor</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1731">Acute myelogenous leukemia</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>ALT-801-Activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia</ProtocolTitle><Trial id="82721"/><TrialEndDateActual/><TrialEndDateCalc>2015-11-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-11-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2013-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase Ib/II trial to evaluate the safety and efficacy of NKTR-214 in combination with entinostat, in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 (programmed death receptor-1) agent</ProtocolTitle><Trial id="341373"/><TrialEndDateActual/><TrialEndDateCalc>2023-05-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="45937">autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1272">Myelodysplastic syndrome</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>Treating High Risk Leukemia With CD40 Ligand and IL-2 Gene Modified Tumor Vaccine</ProtocolTitle><Trial id="184129"/><TrialEndDateActual>2010-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2003-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>1999-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3657">Metastatic breast cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="307">Squamous cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3665">Metastatic non small cell lung cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1069">Metastasis</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Trial id="312527"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3235">Merkel cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Trial id="329566"/><TrialEndDateActual/><TrialEndDateCalc>2021-11-13 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3657">Metastatic breast cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Trial id="329566"/><TrialEndDateActual/><TrialEndDateCalc>2021-11-13 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1744">Mantle cell lymphoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Trial id="337393"/><TrialEndDateActual/><TrialEndDateCalc>2023-06-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-11-17 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-11-17 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="249">Pancreas tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A clinical study to evaluate the safety and efficacy of the triple combination of BXCL-701, NKTR-214 and avelumab for the treatment of patients with pancreatic cancer</ProtocolTitle><Trial id="372194"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="55115">AFTVac</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="2454">Glioblastoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>22</Patients><ProtocolTitle>A phase I/IIa study to evaluate the safety and efficacy of AFTVac in patients with newly diagnosed glioblastoma multiforme</ProtocolTitle><Trial id="67525"/><TrialEndDateActual/><TrialEndDateCalc>2014-05-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2010-06-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="307">Squamous cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>A phase I, safety, tolerability and efficacy study of Multikine in patients with squamous cell head and neck cancer</ProtocolTitle><Trial id="41749"/><TrialEndDateActual/><TrialEndDateCalc>2001-04-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3246">Hormone refractory prostate cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>22</Patients><ProtocolTitle>A phase I safety, pharmacokinetics, and biological pharmacodynamics study of EMD-273066 in patients with prostate cancer</ProtocolTitle><Trial id="37162"/><TrialEndDateActual/><TrialEndDateCalc>2008-04-08 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-06-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3665">Metastatic non small cell lung cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="296922"/><TrialEndDateActual/><TrialEndDateCalc>2021-02-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-05-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-05-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="2380">Bladder cancer</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Trial id="28011"/><TrialEndDateActual/><TrialEndDateCalc>2004-05-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Efficacy</Endpoint><Indication id="307">Squamous cell carcinoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase Ib/II clinical trial to evaluate the anti-cancer activity of the combined agents, avelumab, talazoparib and NKTR-214 and separately avelumab, enzalutamide and NKTR-214 in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN)</ProtocolTitle><Trial id="359129"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3657">Metastatic breast cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Trial id="268769"/><TrialEndDateActual>2018-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3713">Advanced solid tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Trial id="268769"/><TrialEndDateActual>2018-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3657">Metastatic breast cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>283</Patients><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="281291"/><TrialEndDateActual/><TrialEndDateCalc>2020-06-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3664">Metastatic prostate cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3713">Advanced solid tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="623">Head and neck tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>A phase II, multi-center, clinico-pathological efficacy study of neo-adjuvant Multikine immunotherapy, in patients with oral squamous cell carcinoma (OSCC)</ProtocolTitle><Trial id="41890"/><TrialEndDateActual/><TrialEndDateCalc>2002-12-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1998-12-03 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1069">Metastasis</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>165</Patients><ProtocolTitle>A Randomized Study of NKTR-214 Plus Nivolumab and of Reference Chemotherapy in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer With Low PD-L1 Expression</ProtocolTitle><Trial id="364590"/><TrialEndDateActual/><TrialEndDateCalc>2023-02-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-05-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-29 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1771">Transitional cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>165</Patients><ProtocolTitle>A Randomized Study of NKTR-214 Plus Nivolumab and of Reference Chemotherapy in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer With Low PD-L1 Expression</ProtocolTitle><Trial id="364590"/><TrialEndDateActual/><TrialEndDateCalc>2023-02-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-05-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-29 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74941">SO-C101</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3713">Advanced solid tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A first-in-human, phase I/Ib study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in selected patients with advanced/metastatic solid tumors</ProtocolTitle><Trial id="352089"/><TrialEndDateActual/><TrialEndDateCalc>2022-09-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-05-31 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="2718">Histiocytoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Trial id="312527"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74941">SO-C101</Drug><Endpoint>Efficacy</Endpoint><Indication id="725">Solid tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase I, clinical study of SO-C101 in patients with both solid tumors and hematological malignancies</ProtocolTitle><Trial id="352032"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="92317">TILT-123</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="725">Solid tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A trial to evaluate TILT-123 in combination with CAR T-cell therapy for solid tumors</ProtocolTitle><Trial id="375774"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="307">Squamous cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A phase II, multi-center, safety and efficacy study of neoadjuvant immunotherapy with Multikine, in patients with squamous cell carcinoma of the head and neck</ProtocolTitle><Trial id="41761"/><TrialEndDateActual/><TrialEndDateCalc>2003-03-24 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1999-03-25 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Efficacy</Endpoint><Indication id="307">Squamous cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>A phase I/II, multi-center, clinico-pathological study of Multikine in patients with advanced primary oral squamous cell carcinoma</ProtocolTitle><Trial id="41872"/><TrialEndDateActual/><TrialEndDateCalc>2002-12-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1998-12-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1235">Cervical dysplasia</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>8</Patients><ProtocolTitle>A phase I, dose-escalating safety study of immunotherapy with the leukocyte interleukin injection Multikine for the treatment of human papilloma virus (HPV) induced cervical dysplasia, in HIV patients</ProtocolTitle><Trial id="41727"/><TrialEndDateActual/><TrialEndDateCalc>2003-09-21 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2001-05-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3246">Hormone refractory prostate cancer</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations</ProtocolTitle><Trial id="369648"/><TrialEndDateActual/><TrialEndDateCalc>2023-04-08 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="307">Squamous cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>928</Patients><ProtocolTitle>Efficacy and Safety Study of Leukocyte Interleukin, Injection (LI) to Treat Cancer of the Oral Cavity</ProtocolTitle><Trial id="73333"/><TrialEndDateActual/><TrialEndDateCalc>2014-12-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Efficacy</Endpoint><Indication id="623">Head and neck tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase Ib/II clinical trial to evaluate the anti-cancer activity of the combined agents, avelumab, talazoparib and NKTR-214 and separately avelumab, enzalutamide and NKTR-214 in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN)</ProtocolTitle><Trial id="359129"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3466">Metastatic bladder cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Trial id="268769"/><TrialEndDateActual>2018-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="4250">Metastatic renal cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Trial id="268769"/><TrialEndDateActual>2018-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="158">HIV infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>14</Patients><ProtocolTitle>A phase I study of Multikine to evaluate its safety and to determine its effect on various immune system responses</ProtocolTitle><Trial id="9465"/><TrialEndDateActual/><TrialEndDateCalc>1999-08-04 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>1998-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>1998-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>1997-06-03 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3466">Metastatic bladder cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>283</Patients><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="281291"/><TrialEndDateActual/><TrialEndDateCalc>2020-06-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="296922"/><TrialEndDateActual/><TrialEndDateCalc>2021-02-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-05-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-05-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70160">salmonella-IL-2 cancer therapy (oral, cancer), Botanic Oil Innovations</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="725">Solid tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>22</Patients><ProtocolTitle>IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread</ProtocolTitle><Trial id="74920"/><TrialEndDateActual>2014-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-05-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3658">Metastatic colorectal cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3666">Metastatic stomach cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="989">Colorectal tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>27</Patients><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Trial id="28529"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-10-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="3713">Advanced solid tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>6</Patients><ProtocolTitle>An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors</ProtocolTitle><Trial id="360513"/><TrialEndDateActual/><TrialEndDateCalc>2022-05-18 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-02 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-02 00:00:00</TrialEndDateGiven><TrialStartDate>2019-02-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="92317">TILT-123</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase I clinical trial to evaluate safety of TILT-123 in patients with metastatic melanoma</ProtocolTitle><Trial id="341809"/><TrialEndDateActual/><TrialEndDateCalc>2023-08-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-09-30 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1743">Lymphoplasmacytic lymphoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Trial id="337393"/><TrialEndDateActual/><TrialEndDateCalc>2023-06-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-11-17 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-11-17 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="3256">Stage III melanoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>764</Patients><ProtocolTitle>A Study of NKTR-214 Combined With Nivolumab versus Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma</ProtocolTitle><Trial id="350572"/><TrialEndDateActual/><TrialEndDateCalc>2022-09-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2025-03-15 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2025-03-15 00:00:00</TrialEndDateGiven><TrialStartDate>2018-09-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="623">Head and neck tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A phase II, multi-center, safety and efficacy study of neoadjuvant immunotherapy with Multikine, in patients with squamous cell carcinoma of the head and neck</ProtocolTitle><Trial id="41761"/><TrialEndDateActual/><TrialEndDateCalc>2003-03-24 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1999-03-25 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Efficacy</Endpoint><Indication id="276">Prostate tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>A clinical efficacy study of immunotherapy with Multikine in treatment-naive prostate cancer patients</ProtocolTitle><Trial id="41721"/><TrialEndDateActual/><TrialEndDateCalc>2002-12-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1999-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="760">Brain tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>283</Patients><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="281291"/><TrialEndDateActual/><TrialEndDateCalc>2020-06-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="55115">AFTVac</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1767">Hepatocellular carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>41</Patients><ProtocolTitle>A phase IIb, randomized, safety and efficacy study of AFTVac in patients with hepatocellular carcinoma</ProtocolTitle><Trial id="37159"/><TrialEndDateActual/><TrialEndDateCalc>2007-05-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-03-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="55115">AFTVac</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1767">Hepatocellular carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>A phase I/IIa, safety and efficacy study of AFTVac in hepatocellular carcinoma patients</ProtocolTitle><Trial id="37218"/><TrialEndDateActual/><TrialEndDateCalc>2005-06-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2002-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="623">Head and neck tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>A pilot study to evaluate the effects of VB10.NEO in combination with NKTR-214 in patients with squamous cell carcinoma of the head and neck</ProtocolTitle><Trial id="354207"/><TrialEndDateActual/><TrialEndDateCalc>2023-12-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-12-31 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="799">Ovary tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Determine if Either of Two Doses of Study Drug Given With a Low-Dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-Based Second-Line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression</ProtocolTitle><Trial id="35819"/><TrialEndDateActual>2008-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-07-07 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="28450">AIC-284</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1069">Metastasis</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A phase I clinical trial to evaluate the safety and efficacy of BAY-50-4798 in the treatment of patients with advanced renal cell carcinoma or melanoma</ProtocolTitle><Trial id="286299"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="194">Sarcoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Trial id="268769"/><TrialEndDateActual>2018-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3665">Metastatic non small cell lung cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Trial id="268769"/><TrialEndDateActual>2018-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="28450">AIC-284</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="158">HIV infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>A phase I/II safety, tolerability, pharmacokinetics, and efficacy study of an IL-2 antagonist BAY-50-4798, in HIV patients</ProtocolTitle><Trial id="9220"/><TrialEndDateActual/><TrialEndDateCalc>2006-04-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-02-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="2446">Leiomyosarcoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="55115">AFTVac</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="2454">Glioblastoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>22</Patients><ProtocolTitle>A phase I/IIa, prospective clinical trial to evaluate the safety and efficacy of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma multiforme</ProtocolTitle><Trial id="80200"/><TrialEndDateActual/><TrialEndDateCalc>2015-05-07 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2011-05-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="92317">TILT-123</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="725">Solid tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase I trial to evaluate TILT-123 in combination with PD-1 or PD-L1 blockade therapy in CPI-refractory solid tumors</ProtocolTitle><Trial id="375764"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3713">Advanced solid tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Trial id="329566"/><TrialEndDateActual/><TrialEndDateCalc>2021-11-13 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3866">Metastatic ovary cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Trial id="329566"/><TrialEndDateActual/><TrialEndDateCalc>2021-11-13 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="4250">Metastatic renal cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Trial id="329566"/><TrialEndDateActual/><TrialEndDateCalc>2021-11-13 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1746">Marginal zone B-cell lymphoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Trial id="337393"/><TrialEndDateActual/><TrialEndDateCalc>2023-06-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-11-17 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-11-17 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1749">Diffuse large B-cell lymphoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Trial id="337393"/><TrialEndDateActual/><TrialEndDateCalc>2023-06-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-11-17 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-11-17 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="105120">CUE-101</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="307">Squamous cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>50</Patients><ProtocolTitle>A Phase I Study in Patients With HPV+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</ProtocolTitle><Trial id="383734"/><TrialEndDateActual/><TrialEndDateCalc>2023-06-19 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-11-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="105120">CUE-101</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="3673">Metastatic head and neck cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>50</Patients><ProtocolTitle>A Phase I Study in Patients With HPV+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</ProtocolTitle><Trial id="383734"/><TrialEndDateActual/><TrialEndDateCalc>2023-06-19 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-11-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="623">Head and neck tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>A phase I, safety, tolerability and efficacy study of Multikine in patients with squamous cell head and neck cancer</ProtocolTitle><Trial id="41749"/><TrialEndDateActual/><TrialEndDateCalc>2001-04-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55115">AFTVac</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="2454">Glioblastoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>A phase I, pilot study to evaluate safety, feasibility and clinical response of AFTVac in glioblastoma multiforme patients</ProtocolTitle><Trial id="37075"/><TrialEndDateActual/><TrialEndDateCalc>2011-05-26 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2007-06-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>283</Patients><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="281291"/><TrialEndDateActual/><TrialEndDateCalc>2020-06-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3665">Metastatic non small cell lung cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>283</Patients><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="281291"/><TrialEndDateActual/><TrialEndDateCalc>2020-06-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1771">Transitional cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="296922"/><TrialEndDateActual/><TrialEndDateCalc>2021-02-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-05-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-05-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="45937">autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1731">Acute myelogenous leukemia</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>Treating High Risk Leukemia With CD40 Ligand and IL-2 Gene Modified Tumor Vaccine</ProtocolTitle><Trial id="184129"/><TrialEndDateActual>2010-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2003-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>1999-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57922">NHS-IL2-LT</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="3713">Advanced solid tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>48</Patients><ProtocolTitle>EMD-521873 in Advanced Solid Tumors, MTD Finding</ProtocolTitle><Trial id="62646"/><TrialEndDateActual>2012-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-08-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="45937">autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1734">Chronic lymphocytic leukemia</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>2</Patients><ProtocolTitle>Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide</ProtocolTitle><Trial id="87716"/><TrialEndDateActual>2015-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-09-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2013-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3669">Metastatic pancreas cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="1771">Transitional cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="623">Head and neck tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="307">Squamous cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>A phase II, multi-center, clinico-pathological efficacy study of neo-adjuvant Multikine immunotherapy, in patients with oral squamous cell carcinoma (OSCC)</ProtocolTitle><Trial id="41890"/><TrialEndDateActual/><TrialEndDateCalc>2002-12-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1998-12-03 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="2447">Liposarcoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Trial id="312527"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1262">Non-small-cell lung cancer</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>27</Patients><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Trial id="28529"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-10-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="799">Ovary tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>27</Patients><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Trial id="28529"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-10-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1069">Metastasis</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Trial id="337393"/><TrialEndDateActual/><TrialEndDateCalc>2023-06-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-11-17 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-11-17 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Efficacy</Endpoint><Indication id="49">Breast tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>A clinical efficacy study of Multikine in patients with breast cancer</ProtocolTitle><Trial id="41707"/><TrialEndDateActual/><TrialEndDateCalc>2004-03-23 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-05-23 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="623">Head and neck tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A phase II, safety and efficacy study of Multikine in patients with head and neck cancer</ProtocolTitle><Trial id="41758"/><TrialEndDateActual/><TrialEndDateCalc>2000-01-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1996-02-27 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="57922">NHS-IL2-LT</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>MSB-0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma</ProtocolTitle><Trial id="159844"/><TrialEndDateActual/><TrialEndDateCalc>2017-12-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="28450">AIC-284</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="158">HIV infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>82</Patients><ProtocolTitle>Safety and Efficacy of BAY-50-4798 in Patients With HIV Infection</ProtocolTitle><Trial id="13695"/><TrialEndDateActual>2005-03-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2005-03-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2005-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2005-03-01 00:00:00</TrialEndDateGiven><TrialStartDate>2002-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="57922">NHS-IL2-LT</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="3665">Metastatic non small cell lung cancer</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>EMD-521873 Plus Radiotherapy in Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Trial id="51498"/><TrialEndDateActual>2012-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-09-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3713">Advanced solid tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>283</Patients><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="281291"/><TrialEndDateActual/><TrialEndDateCalc>2020-06-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57922">NHS-IL2-LT</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="319">Non-Hodgkin lymphoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>48</Patients><ProtocolTitle>EMD-521873 in Advanced Solid Tumors, MTD Finding</ProtocolTitle><Trial id="62646"/><TrialEndDateActual>2012-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-08-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1232">Condyloma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>8</Patients><ProtocolTitle>Study of Leukocyte Interleukin Injection for Treatment of Perianal Warts</ProtocolTitle><Trial id="286956"/><TrialEndDateActual>2018-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-09-27 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="194">Sarcoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="740">Uterus tumor</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1772">Osteosarcoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Trial id="312527"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>764</Patients><ProtocolTitle>A Study of NKTR-214 Combined With Nivolumab versus Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma</ProtocolTitle><Trial id="350572"/><TrialEndDateActual/><TrialEndDateCalc>2022-09-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2025-03-15 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2025-03-15 00:00:00</TrialEndDateGiven><TrialStartDate>2018-09-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1771">Transitional cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Trial id="329566"/><TrialEndDateActual/><TrialEndDateCalc>2021-11-13 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="194">Sarcoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Trial id="329566"/><TrialEndDateActual/><TrialEndDateCalc>2021-11-13 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3658">Metastatic colorectal cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Trial id="329566"/><TrialEndDateActual/><TrialEndDateCalc>2021-11-13 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3246">Hormone refractory prostate cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>5</Patients><ProtocolTitle>A clinical safety, feasibility and efficacy study of Multikine in patients with prostate cancer</ProtocolTitle><Trial id="41716"/><TrialEndDateActual/><TrialEndDateCalc>2000-03-06 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1996-05-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3466">Metastatic bladder cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="296922"/><TrialEndDateActual/><TrialEndDateCalc>2021-02-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-05-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-05-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7401">Multikine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1232">Condyloma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4</Patients><ProtocolTitle>Safety Study of Multikine in the Treatment of Perianal Warts</ProtocolTitle><Trial id="182223"/><TrialEndDateActual>2016-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-09-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="307">Squamous cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>A pilot study to evaluate the effects of VB10.NEO in combination with NKTR-214 in patients with squamous cell carcinoma of the head and neck</ProtocolTitle><Trial id="354207"/><TrialEndDateActual/><TrialEndDateCalc>2023-12-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-12-31 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="4250">Metastatic renal cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>283</Patients><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="281291"/><TrialEndDateActual/><TrialEndDateCalc>2020-06-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="1771">Transitional cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>283</Patients><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Trial id="281291"/><TrialEndDateActual/><TrialEndDateCalc>2020-06-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="28450">AIC-284</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1766">Renal cell carcinoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A phase I clinical trial to evaluate the safety and efficacy of BAY-50-4798 in the treatment of patients with advanced renal cell carcinoma or melanoma</ProtocolTitle><Trial id="286299"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="28450">AIC-284</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A phase I clinical trial to evaluate the safety and efficacy of BAY-50-4798 in the treatment of patients with advanced renal cell carcinoma or melanoma</ProtocolTitle><Trial id="286299"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Efficacy</Endpoint><Indication id="3246">Hormone refractory prostate cancer</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase Ib/II clinical trial to evaluate the anti-cancer activity of the combined agents, avelumab, talazoparib and NKTR-214 and separately avelumab, enzalutamide and NKTR-214 in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN)</ProtocolTitle><Trial id="359129"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Trial id="268769"/><TrialEndDateActual>2018-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3658">Metastatic colorectal cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Trial id="268769"/><TrialEndDateActual>2018-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="4250">Metastatic renal cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase III clinical study to assess the effect of bempegaldesleukin in combination with nivolumab compared to tyrosine kinase inhibitor (TKI) monotherapy in patients with advanced metastatic renal cell carcinoma</ProtocolTitle><Trial id="372111"/><TrialEndDateActual/><TrialEndDateCalc>2022-11-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="3668">Metastatic lung cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="2380">Bladder cancer</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>52</Patients><ProtocolTitle>A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer</ProtocolTitle><Trial id="88603"/><TrialEndDateActual/><TrialEndDateCalc>2016-02-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-04-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>22</Patients><ProtocolTitle>Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma</ProtocolTitle><Trial id="62586"/><TrialEndDateActual>2013-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-01-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="86441">ALKS-4230</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="4250">Metastatic renal cell carcinoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Trial id="263216"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase III registrational trial of NKTR-214 in first-line advanced melanoma patients</ProtocolTitle><Trial id="349635"/><TrialEndDateActual/><TrialEndDateCalc>2022-08-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2018-09-30 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="2443">Angiosarcoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Trial id="312527"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="2444">Chondrosarcoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Trial id="312527"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="194">Sarcoma</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Trial id="312527"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="21065">tucotuzumab celmoleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="276">Prostate tumor</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>27</Patients><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Trial id="28529"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-10-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="3257">Stage IV melanoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Trial id="329566"/><TrialEndDateActual/><TrialEndDateCalc>2021-11-13 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="77588">bempegaldesleukin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1745">Follicle center lymphoma</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Trial id="337393"/><TrialEndDateActual/><TrialEndDateCalc>2023-06-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-11-17 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-11-17 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row></Rowset>